Abstract
The successful development of personalized therapy depends on the identification of a specific molecular target that drives cancer growth and the subsequent validation of a clinically applicable biomarker molecular test. In non-small-cell lung carcinomas (NSCLCs), analysis of molecular changes is best exemplified by treating patients with tyrosine kinase inhibitors (TKIs) when their tumors harbor activating epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) gene rearrangements. This chapter describes the important methodological and practical issues that represent significant challenges for personalized therapy of NSCLC. The routine utilization of advanced technologies and molecular information, including the application of the NGS tools, coupled with appropriate data management and analysis, may help us to better develop personalized therapies in lung cancer.
Original language | English (US) |
---|---|
Title of host publication | Cancer Consult |
Subtitle of host publication | Expertise for Clinical Practice |
Publisher | Wiley-Blackwell |
Pages | 480-485 |
Number of pages | 6 |
ISBN (Electronic) | 9781118589199 |
ISBN (Print) | 9781118589212 |
DOIs | |
State | Published - Jun 20 2014 |
Keywords
- Anaplastic lymphoma kinase (ALK)
- Epidermal growth factor receptor (EGFR)
- Non-small-cell lung carcinomas (NSCLCs)
ASJC Scopus subject areas
- General Medicine